Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

149.36 -0.34 (-0.23%)
Streaming Delayed Price Updated: 10:48 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
56 57 Next >
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
3 Crazy Good Stocks to Buy With $500 Right Now ↗
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
News headline image
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations ↗
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis. 
Via Benzinga
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today
Via Get News
News headline image
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
News headline image
Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
News headline image
Is NYSE:NVS a Good Fit for Dividend Investing? ↗
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
Novartis Sues to Block Maryland's New Drug Discount Law ↗
Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharmacies contracting with hospitals and clinics. 
Via Benzinga
Topics Lawsuit
News headline image
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety ↗
Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, showing significant symptom improvement and a favorable safety profile up to... 
Via Benzinga
News headline image
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
News headline image
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
News headline image
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
3 Magnificent Stocks That Are Passive Income Machines ↗
These three companies have track records that should please investors. 
Via The Motley Fool
News headline image
The 3 Best Mutual Funds to Buy in May 2024 ↗
Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital. 
Via InvestorPlace
News headline image
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths' ↗
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
News headline image
3 Biotech Stocks to Sell in May Before They Crash & Burn ↗
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
News headline image
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease ↗
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Axmed raises $2 million to transform access to critical medicines in low and middle income countries
Axmed’s B2B marketplace aggregates demand for critical medicines in underserved regions to improve the availability, affordability, and distribution of life-saving medicine. 
Via News Direct
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
News headline image
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
2 Magnificent Dividend Stocks to Hold for the Next Decade ↗
The dividend is just one reason to buy these stocks. 
Via The Motley Fool
News headline image
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
News headline image
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib ↗
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds... 
Via Benzinga
News headline image
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales ↗
The company is projected to bring in increasing sales through at least 2029. 
Via Investor's Business Daily
News headline image
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
News headline image
What's Going On With Pfizer Stock On Thursday? ↗
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
News headline image
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
News headline image
Why Novartis Stock Topped the Market on Tuesday ↗
A double beat on the latest quarterly results and raised guidance made investors happy. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.